Metraipolis › archive › dc_5ff5b3db2f86

Clinical outcomes of agalsidase Beta (fabrazyme) in Chinese fabry disease patients with proteinuria: a case series — Europe PMC PMID:42403387

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42403387
DOI
10.3389/fped.2026.1839303
License (as archived)
solo-consultazione
Archived
2026-10-19T09:13:21.448Z
SHA-256 of the archived text
1f45a884807e425b15dcb603a6aa1375011c2e87983c5d54501425d79d9c08a2
Stable URL of this page
https://metraipolis.com/documento/dc_5ff5b3db2f86

How to cite

Clinical outcomes of agalsidase Beta (fabrazyme) in Chinese fabry disease patients with proteinuria: a case series — Europe PMC PMID:42403387 — Europe PMC (en), https://europepmc.org/article/MED/42403387 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_5ff5b3db2f86 (Metraipolis archive dc_5ff5b3db2f86, sha256 1f45a884807e425b15dcb603a6aa1375011c2e87983c5d54501425d79d9c08a2)
BibTeX
@misc{dc5ff5b3db2f86,
  title = {Clinical outcomes of agalsidase Beta (fabrazyme) in Chinese fabry disease patients with proteinuria: a case series — Europe PMC PMID:42403387},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42403387},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_5ff5b3db2f86; sha256 1f45a884807e425b15dcb603a6aa1375011c2e87983c5d54501425d79d9c08a2},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42403387. Agents can read the archived copy with the MCP tool read_document.